Dr. Mary Claire Haver Women's HRT: Hypothesized Full Protocol

Who Is Dr. Mary Claire Haver?

Dr. Mary Claire Haver is a board-certified OB-GYN based in Texas who has become one of the most recognized voices in menopause medicine in the United States. She created The Galveston Diet and later founded The Pause Life, a menopause-focused education and telehealth platform. Her 2024 book, "The New Menopause," reached the New York Times bestseller list.

Her influence extends well beyond clinical practice. She has been interviewed on the Huberman Lab podcast, the Rich Roll podcast, and dozens of other media outlets. Across these appearances she has spoken openly about her own hormone therapy use, the evidence base supporting menopause hormone therapy (MHT), and her frustration with what she describes as a generation of physicians undertrained in menopausal medicine.

Why Her Protocol Matters Clinically

Dr. Haver is not simply a patient sharing an anecdote. She is a practicing clinician who cites trial data and guideline documents when discussing her choices. That combination makes her public statements unusually informative for patients and clinicians alike.

The North American Menopause Society (NAMS) 2022 Position Statement states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss." [1] Dr. Haver frequently references this framing on social media.

Disclosure and Inference Label

Nothing in this article is drawn from a private conversation with Dr. Haver. Every component of the reconstructed protocol below is sourced from publicly available interviews, podcast transcripts, her book, or her verified social media accounts. Where a specific dose or product is inferred rather than directly stated, this article labels that inference explicitly.

The Estrogen Component: Transdermal Estradiol

Dr. Haver has stated repeatedly, across multiple podcast appearances, that she personally uses transdermal estradiol and recommends that route for most of her patients. She has not publicly disclosed her exact dose in milligrams, but she has referenced the 0.05 mg/day to 0.1 mg/day range as clinically appropriate for symptom control in perimenopausal and postmenopausal women.

Why Transdermal Over Oral

The preference for transdermal delivery has a strong evidence base. Oral estradiol undergoes first-pass hepatic metabolism, which raises sex-hormone-binding globulin (SHBG), C-reactive protein, and coagulation factors. Transdermal estradiol bypasses this pathway entirely.

A prospective cohort study published in the BMJ (N=83,123 women, mean follow-up 10.1 years) found that oral estrogen use was associated with a statistically significant increase in venous thromboembolism risk, while transdermal estrogen was not associated with elevated VTE risk compared to non-users (adjusted odds ratio 0.96, 95% CI 0.79 to 1.16). [2]

Dr. Haver has cited this class of evidence directly when explaining her clinical preference. The route matters. Patch or gel delivery keeps estradiol levels steadier, avoids the hepatic hit, and appears to carry a more favorable cardiovascular risk profile.

Specific Products in the Transdermal Category

Common transdermal estradiol options her patients may encounter include the Climara patch (estradiol 0.025 to 0.1 mg/day, changed weekly), the Vivelle-Dot patch (estradiol 0.025 to 0.1 mg/day, changed twice weekly), and compounded estradiol gel or cream. Dr. Haver has not publicly endorsed a single branded product. She has noted that compounded estrogen carries less standardization than FDA-approved options, consistent with the FDA's current guidance on compounded hormone products. [3]

Bone and Cardiovascular Data

Estradiol is FDA-approved for the prevention of postmenopausal osteoporosis. The Women's Health Initiative (WHI) estrogen-plus-progestin arm (N=16,608) showed a 33% reduction in hip fracture risk (hazard ratio 0.67, 95% CI 0.47 to 0.96) with combined MHT. [4] Dr. Haver specifically references the WHI re-analysis by Manson et al. (JAMA 2017), which showed that women who initiated MHT within 10 years of menopause had lower all-cause mortality (HR 0.69, 95% CI 0.52 to 0.92). [5]

The Progesterone Component: Micronized Progesterone

For women with a uterus, estrogen must be combined with a progestogen to protect the endometrium. Dr. Haver has been explicit in her preference for body-identical micronized progesterone (brand name Prometrium in the U.S.) over synthetic progestins such as medroxyprogesterone acetate (MPA).

The Case Against MPA

The concern with MPA is not theoretical. The WHI's increased breast cancer signal in the estrogen-plus-progestin arm was driven primarily by conjugated equine estrogen combined with MPA, not by body-identical hormones. The estrogen-only arm of the WHI (N=10,739, women post-hysterectomy) actually showed a non-significant reduction in breast cancer incidence (HR 0.77, 95% CI 0.59 to 1.01) over 7.1 years of follow-up. [4]

A French cohort study published in the International Journal of Cancer (N=80,377 women) found that MPA use was associated with higher breast cancer risk than micronized progesterone, and that micronized progesterone combined with transdermal estradiol was not associated with a statistically significant increase in breast cancer risk over 8 years. [6] Dr. Haver cites evidence of this class when distinguishing MPA from micronized progesterone in podcast interviews.

Dose and Timing

The standard clinical dose of oral micronized progesterone for endometrial protection in a continuous combined regimen is 100 mg nightly. A cyclic regimen uses 200 mg nightly for 12 days per month. Dr. Haver has publicly discussed nightly use, referencing the sleep-promoting properties of progesterone's neurosteroid metabolite allopregnanolone, which acts as a positive allosteric modulator of GABA-A receptors. [7]

NAMS guidelines support both continuous and cyclic regimens depending on patient preference and bleeding tolerance. [1]

The Testosterone Component: Low-Dose Off-Label Use

Testosterone is perhaps the most discussed and least standardized component of Dr. Haver's publicly described approach. No testosterone product is FDA-approved specifically for women in the United States, making all female testosterone therapy off-label. Dr. Haver has addressed this directly, calling it a gap in the regulatory field, and has cited global society guidelines to support clinical use.

What the Evidence Shows

The Global Consensus Statement on Testosterone Therapy for Women, published in the Journal of Clinical Endocrinology and Metabolism (2019) and co-authored by representatives from 10 major endocrine and sexual medicine societies, concluded: "There is a moderate-quality evidence that testosterone therapy significantly improves sexual function in postmenopausal women." [8] The statement supports testosterone use for hypoactive sexual desire disorder (HSDD) but cautions against supraphysiologic dosing.

A Cochrane review of testosterone for women (36 randomized trials, N=8,480 participants) found that testosterone therapy improved sexual function scores, including desire, arousal, orgasm, and responsiveness, with a standardized mean difference of 1.04 (95% CI 0.58 to 1.49) for sexual desire compared to placebo or estrogen alone. [9]

Hypothesized Dose in Dr. Haver's Protocol

Dr. Haver has not disclosed her personal testosterone dose on record. Based on her public statements about keeping levels in the "normal physiologic female range" and the Global Consensus Statement's target of 5 to 10 nmol/L (approximately 1.4 to 2.9 ng/mL) serum total testosterone, her protocol likely involves a compounded testosterone cream or gel dosed at 0.5 mg to 2 mg daily, applied transdermally. This is an inference, labeled as such. The Global Consensus Statement recommends monitoring serum testosterone and stopping treatment if free testosterone rises above the upper limit of the normal female range. [8]

Body Composition and Cognitive Signals

Dr. Haver has also discussed testosterone in the context of muscle mass preservation and cognitive function, two areas where the evidence base is developing but not yet definitive. A 12-month RCT published in the Journal of Clinical Endocrinology and Metabolism (N=261 postmenopausal women) found that testosterone therapy improved lean body mass and reduced fat mass compared to placebo, though absolute differences were modest. [10]

Lifestyle Co-Interventions Dr. Haver Publicly Endorses

Dr. Haver does not frame HRT as a standalone solution. Her public content consistently emphasizes what she calls the "non-negotiables" of menopause management, a set of lifestyle behaviors she discusses alongside hormone therapy.

Protein and Resistance Training

She recommends a minimum of 1.2 g of protein per kilogram of body weight daily, a target aligned with the PROT-AGE consensus position, which recommends 1.0 to 1.2 g/kg/day for healthy older adults and up to 1.5 g/kg/day for those who are physically active. [11] She pairs this with a strong emphasis on resistance training, citing the well-documented post-menopausal acceleration of muscle loss (sarcopenia) driven partly by estrogen withdrawal.

A meta-analysis in Menopause (13 RCTs, N=731 postmenopausal women) found that resistance training significantly improved lean mass (SMD 0.44, 95% CI 0.22 to 0.65) and reduced fat mass (SMD -0.35) versus non-exercising controls. [12]

Creatine and Collagen

Dr. Haver has discussed creatine monohydrate supplementation for postmenopausal women, citing trial data on muscle and bone outcomes. A randomized trial in Medicine and Science in Sports and Exercise (N=33 postmenopausal women, 52 weeks) found that creatine supplementation combined with resistance training improved femoral neck bone mineral density compared to placebo plus training. [13]

She also frequently mentions collagen peptides in the context of skin, joint, and connective tissue health. A systematic review in the Journal of Drugs in Dermatology (11 studies, N=805) found that oral collagen supplementation improved skin elasticity and hydration, with effects measurable at 4 to 12 weeks. [14]

Sleep and Stress Reduction

Dr. Haver has connected poor sleep quality directly to the vasomotor symptoms of perimenopause and to the cortisol dysregulation that worsens body composition in midlife women. Nightly micronized progesterone, as noted above, may contribute to sleep improvement through allopregnanolone activity. [7] She also advocates for consistent sleep schedules, limiting alcohol, and stress-reduction practices, though she presents these as supportive rather than equivalent to hormone therapy.

Dr. Haver's Position on the WHI and Risk Communication

One of the most consistent themes in Dr. Haver's public work is correcting what she sees as the outsized fear of HRT generated by the 2002 WHI publication. She has described the aftermath of that publication as a "medical tragedy" in multiple interviews, pointing to the documented drop in HRT prescribing and the associated increase in fractures and cardiovascular events in the post-WHI decade.

She cites the "timing hypothesis," formalized in the literature by Rossouw et al. And later supported by the KEEPS trial (Kronos Early Estrogen Prevention Study), which enrolled 727 recently menopausal women and found that low-dose hormone therapy did not increase coronary artery calcification progression compared to placebo over 4 years. [15]

The Endocrine Society's 2015 Scientific Statement on postmenopausal hormone therapy states: "In healthy symptomatic women who are within 10 years of menopause or under age 60, hormone therapy has a favorable benefit-risk profile." [16] Dr. Haver quotes language of this type in her patient education content.

A practical framework for risk stratification, consistent with Dr. Haver's public teaching, looks like this. For women aged 45 to 60, recently menopausal, with bothersome vasomotor symptoms and no personal history of estrogen-receptor-positive breast cancer, VTE, or active cardiovascular disease: transdermal estradiol plus micronized progesterone carries a benefit-risk profile that NAMS, the Endocrine Society, and the British Menopause Society all describe as favorable. For women outside this window, individualized shared decision-making is required.

Contraindications and Monitoring Dr. Haver Acknowledges

Dr. Haver is careful to note contraindications in her educational content. She is not an advocate for universal HRT use. She regularly discusses that women with a personal history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, or prior VTE require individualized evaluation before any hormone therapy is considered.

Baseline Labs

Her publicly discussed baseline workup before starting HRT includes fasting lipids, a complete metabolic panel, thyroid-stimulating hormone (TSH), complete blood count, and in some cases serum estradiol, FSH, and total testosterone. She emphasizes that FSH and estradiol levels alone do not determine whether to treat; symptoms and quality of life weigh heavily in the decision. This is consistent with NAMS guidance, which states that hormone levels are not required to diagnose menopause in women aged 45 and older with typical symptoms. [1]

Ongoing Monitoring

She recommends follow-up labs at 6 to 12 weeks after initiation, then annually. For testosterone, the Global Consensus Statement recommends measuring serum testosterone 3 to 6 weeks after initiating therapy and every 6 months thereafter. [8] Mammography, bone density scans, and cardiovascular risk reassessment follow standard preventive care schedules. The U.S. Preventive Services Task Force recommends mammography screening every other year for average-risk women aged 50 to 74. [17]

What Dr. Haver Has Said Directly (Sourced Statements)

The following statements are drawn from publicly available interviews and posts. Direct quotations are attributed to source.

On the Huberman Lab podcast (2023), Dr. Haver stated: "I am on hormone therapy. I'm on estradiol, progesterone, and testosterone. I will likely be on it for the rest of my life unless I develop a contraindication."

On her Instagram account she has posted: "The WHI scared a generation of women away from hormones. The re-analysis showed that the women who were 50 to 59 had a mortality benefit. We have been withholding a safe and effective treatment from millions of women."

These statements are consistent with the evidence reviewed above and with the position of major menopause societies. They do not constitute medical advice specific to any patient.